コンテンツへスキップ
Merck
すべての画像(1)

Key Documents

Y0001058

Dextropropoxyphene hydrochloride

European Pharmacopoeia (EP) Reference Standard

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C22H29NO2 · HCl
CAS番号:
分子量:
375.93
UNSPSCコード:
41116107
NACRES:
NA.24

グレード

pharmaceutical primary standard

APIファミリー

dextropropoxyphene

メーカー/製品名

EDQM

薬剤管理

regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

InChI

1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1

InChI Key

QMQBBUPJKANITL-MYXGOWFTSA-N

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Dextropropoxyphene hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。

その他情報

Sales restrictions may apply.

ピクトグラム

Skull and crossbones

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 3 Oral

保管分類コード

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

申し訳ございませんが、現在この製品のCOAをオンラインで入手できません。

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Wayne A Ray et al.
Pharmacoepidemiology and drug safety, 22(4), 403-412 (2013-02-15)
The opioid analgesic propoxyphene was withdrawn from the US market in 2010, motivated by concerns regarding fatality in overdose and adverse cardiac effects, including prolongation of the QT interval. These concerns were based on case reports, summary vital statistics, and
P Bertin et al.
The journal of nutrition, health & aging, 17(8), 681-686 (2013-10-08)
The main objective of the S.AGES (Elderly Subjects) cohort study is to describe the current therapeutic strategy for chronic pain in non-institutionalised elderly patients in France. In this prospective cohort study, non-institutionalised patients aged 65 years and over with chronic
Nick A Buckley et al.
The Medical journal of Australia, 199(4), 257-260 (2013-08-30)
• The Therapeutic Goods Administration determined in November 2011 that dextropropoxyphene should be removed from the Australian Register of Therapeutic Goods. This is consistent with this drug's removal from the market in many other developed countries. • However, dextropropoxyphene is
Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)